GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » Beneish M-Score

DuoGenic StemCells (ROCO:7607) Beneish M-Score : -2.34 (As of Mar. 14, 2025)


View and export this data going back to 2023. Start your Free Trial

What is DuoGenic StemCells Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.34 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for DuoGenic StemCells's Beneish M-Score or its related term are showing as below:

ROCO:7607' s Beneish M-Score Range Over the Past 10 Years
Min: -2.34   Med: -2.34   Max: -2.34
Current: -2.34

During the past 3 years, the highest Beneish M-Score of DuoGenic StemCells was -2.34. The lowest was -2.34. And the median was -2.34.


DuoGenic StemCells Beneish M-Score Historical Data

The historical data trend for DuoGenic StemCells's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuoGenic StemCells Beneish M-Score Chart

DuoGenic StemCells Annual Data
Trend Dec21 Dec22 Dec23
Beneish M-Score
- - -2.34

DuoGenic StemCells Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beneish M-Score Get a 7-Day Free Trial - - - -2.34 -

Competitive Comparison of DuoGenic StemCells's Beneish M-Score

For the Biotechnology subindustry, DuoGenic StemCells's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DuoGenic StemCells's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where DuoGenic StemCells's Beneish M-Score falls into.



DuoGenic StemCells Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of DuoGenic StemCells for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6588+0.528 * 0.9383+0.404 * 0.6342+0.892 * 1.9917+0.115 * 0.8326
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8064+4.679 * -0.016766-0.327 * 1.5807
=-2.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was NT$3.46 Mil.
Revenue was NT$13.67 Mil.
Gross Profit was NT$4.90 Mil.
Total Current Assets was NT$66.69 Mil.
Total Assets was NT$94.00 Mil.
Property, Plant and Equipment(Net PPE) was NT$23.65 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$7.01 Mil.
Selling, General, & Admin. Expense(SGA) was NT$35.48 Mil.
Total Current Liabilities was NT$10.35 Mil.
Long-Term Debt & Capital Lease Obligation was NT$5.23 Mil.
Net Income was NT$-45.24 Mil.
Gross Profit was NT$0.00 Mil.
Cash Flow from Operations was NT$-43.66 Mil.
Total Receivables was NT$2.64 Mil.
Revenue was NT$6.86 Mil.
Gross Profit was NT$2.31 Mil.
Total Current Assets was NT$54.51 Mil.
Total Assets was NT$82.24 Mil.
Property, Plant and Equipment(Net PPE) was NT$22.68 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$5.33 Mil.
Selling, General, & Admin. Expense(SGA) was NT$22.09 Mil.
Total Current Liabilities was NT$6.99 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1.64 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.46 / 13.667) / (2.637 / 6.862)
=0.253165 / 0.38429
=0.6588

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.308 / 6.862) / (4.899 / 13.667)
=0.336345 / 0.358455
=0.9383

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (66.689 + 23.653) / 94.002) / (1 - (54.512 + 22.679) / 82.24)
=0.038935 / 0.061393
=0.6342

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=13.667 / 6.862
=1.9917

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.334 / (5.334 + 22.679)) / (7.013 / (7.013 + 23.653))
=0.190412 / 0.22869
=0.8326

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(35.476 / 13.667) / (22.087 / 6.862)
=2.595742 / 3.218741
=0.8064

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.228 + 10.354) / 94.002) / ((1.639 + 6.985) / 82.24)
=0.165762 / 0.104864
=1.5807

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-45.236 - 0 - -43.66) / 94.002
=-0.016766

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

DuoGenic StemCells has a M-score of -2.34 suggests that the company is unlikely to be a manipulator.


DuoGenic StemCells Beneish M-Score Related Terms

Thank you for viewing the detailed overview of DuoGenic StemCells's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


DuoGenic StemCells Business Description

Traded in Other Exchanges
N/A
Address
Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.

DuoGenic StemCells Headlines

No Headlines